RBF Capital LLC Reduces Holdings in Keros Therapeutics, Inc. $KROS

RBF Capital LLC decreased its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 45.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,724 shares of the company’s stock after selling 68,276 shares during the quarter. RBF Capital LLC owned 0.27% of Keros Therapeutics worth $1,664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in Keros Therapeutics during the 1st quarter worth approximately $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after acquiring an additional 2,982 shares during the period. Goldman Sachs Group Inc. raised its stake in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the period. Creative Planning raised its stake in Keros Therapeutics by 40.2% during the 2nd quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the period. Finally, Rhumbline Advisers raised its stake in Keros Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after acquiring an additional 7,146 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Insider Buying and Selling

In related news, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 10,958 shares in the company, valued at approximately $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the sale, the director owned 9,767 shares in the company, valued at $104,702.24. This represents a 21.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,425 shares of company stock worth $89,995. Insiders own 22.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Wells Fargo & Company decreased their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Finally, Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $10.03 on Wednesday. The stock has a market cap of $198.49 million, a P/E ratio of -3.33 and a beta of 0.94. Keros Therapeutics, Inc. has a 1 year low of $9.69 and a 1 year high of $22.55. The firm’s 50 day moving average price is $11.16 and its 200-day moving average price is $14.80.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The business had revenue of $0.37 million during the quarter, compared to the consensus estimate of $1.93 million. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.